Want to see SRZN full AI Analyst Report?
SRZN Stock Chart & Stats
$19.73
-$0.60(-3.04%)
At close: 4:00 PM EDT
$19.73
-$0.60(-3.04%)
Day’s Range― - ―
52-Week Range$10.73 - $35.00
Previous CloseN/A
Volume104.46K
Average Volume (3M)25.24K
Market Cap
$276.21M
Enterprise Value$504.92
Total Cash (Recent Filing)$102.04M
Total Debt (Recent Filing)$6.32M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 11, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.13
Shares Outstanding11,753,558
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.60Price Target Upside126.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.81
Revenue Forecast (FY)$10.93M
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA meaningful TTM revenue inflection indicates improving commercial or collaboration receipts that can help fund R&D. If sustained over 2–6 months, this reduces near-term financing pressure and validates program progress or partner activity.
High Gross MarginsVery high gross margins imply favorable product-level economics typical of biologics and scalable therapeutics. Once development succeeds, these margins support operating leverage and durable profitability if operating expenses are controlled.
Board And Governance ContinuityShareholder backing for directors and auditor signals governance stability and management continuity, supporting consistent strategic execution across clinical programs and reducing risk of disruptive leadership changes over the medium term.
Bears Say
Large Net Losses And Cash BurnMassive recurring losses and negative operating cash flow create an enduring liquidity drain. Over 2–6 months this forces reliance on external funding, compresses runway, and can force program cutbacks or accelerated dilution that impair long-term strategy.
Negative Shareholders' EquitySustained negative equity reflects accumulated deficits and erodes balance sheet resilience. It reduces financing flexibility, increases investor scrutiny, and makes equity issuance the likeliest funding path, raising dilution risk and governance pressure.
Heavy Operating Expense BurdenDespite strong gross margins, high R&D and G&A costs prevent profitability. Unless operating expenses are rebalanced or revenues scale materially, the cost base will continue to outpace income, limiting progress toward sustainable profitability.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $10.73 and its highest was $35.00 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $276.21M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Nov 11, 2026 which is in 81 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Aug 06, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$1.288 by $0.878.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.1.
How many shares outstanding does Surrozen have?
Surrozen has 11,753,558 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$0.41 in its last earnings report, beating expectations of -$1.288. Following the earnings report the stock price went up 18.392%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.60 (126.05% Upside)
$44.60 (126.05% Upside)
Blogger Sentiment
Bullish
SRZN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 56.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 27.8%
Last 30 Days ▼ 27.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.57%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$44.60
▲(126.05% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
43.85% Insiders
1.87% Mutual Funds
5.73% Other Institutional Investors
42.35% Public Companies and
Individual Investors